首页> 外文期刊>Journal of Thoracic Disease >PET-CT limitations in early stage non-small cell lung cancer: to whom more aggressive approach in radiotherapy and surgery should be directed?
【24h】

PET-CT limitations in early stage non-small cell lung cancer: to whom more aggressive approach in radiotherapy and surgery should be directed?

机译:早期非小细胞肺癌的PET-CT局限性:应针对谁在放射治疗和外科手术中采用更具攻击性的方法?

获取原文
           

摘要

This editorial comments on the study by Paravati et al. , which reported on the incidence of occult regional lymph node metastases in PET-CT T1T2N0 non-small cell lung cancer (NSCLC) patients. A central location and the size of the tumor were shown to be the strongest predictors of the risk of occult nodal disease. Authors comment that in view of limitations of modern imaging, as well as the reported negative predictive value (NPV) of invasive staging methods, the choice of therapeutic options as the extent of surgery (lobectomy or sublobar resection) or radiotherapy [stereotactic body radiation therapy (SBRT) or conformal radiotherapy (RT) with some forms of elective nodal irradiation (ENI)] should consider tumor’s characteristics and not be based only on imaging and invasive staging modalities.
机译:这篇社论评论了Paravati等人的研究。 ,该研究报道了PET-CT T1T2N0非小细胞肺癌(NSCLC)患者的隐匿性区域淋巴结转移的发生率。肿瘤的中心位置和大小被证明是隐匿性淋巴结病风险的最强预测因子。作者评论说,鉴于现代影像学的局限性以及所报道的有创分期方法的阴性预测值(NPV),应选择手术方式(肺叶切除术或大叶下切除术)或放射疗法(立体定向放射治疗)的治疗选择(SBRT)或采用某些形式的选择性淋巴结照射(ENI)的适形放疗(RT)]应考虑肿瘤的特征,而不应仅基于影像学和侵入性分期方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号